Podcasts about elotuzumab

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include:Strategies for monitoring for disease progressionDisease, therapy, and patient considerations for treatment selection at first relapseNursing implications and supportive care considerations for patients receiving therapy for relapsed diseasePresenter:Charise Gleason, MSN, NP-BC, AOCNPAdvanced Practice Provider ChiefWinship Cancer InstituteAdjunct FacultyNell Hodgson Woodruff School of NursingEmory UniversityAtlanta, GeorgiaCE/AAPA credit available by visiting the online program: https://bit.ly/3ee9IvsLink to full program, including downloadable slidesets:https://bit.ly/3ee9Ivs

In this episode,  Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:Approaches for managing smoldering multiple myelomaInsights on new strategies for managing newly diagnosed multiple myelomaIncorporating newly approved agents in the frontline and early relapse settingChoosing and sequencing BCMA-targeted therapiesManaging patients with refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaThomas G. Martin, MDClinical Professor of MedicineAssociate Director, Myeloma ProgramUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaPhilippe Moreau, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital Hôtel-DieuNantes, FranceS. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, MinnesotaJesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainSupported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.Link to full program, including downloadable slidesets and expert commentaries:https://bit.ly/39MWNid 

In this episode, we tackle the recent papers in the New England Journal of Medicine on "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma" and "Immunotherapy Combinations in Multiple Myeloma", as well as a comment in The Lancet Oncology's editorial "9 Weeks That Matter for Patients With Gastric Cancer". We conclude with an interview with Dr. Erick Turner of OHSU on the FDA, regulatory capture, selective reporting, and transparency. Elo-pom-dex: http://doi.org/10.1056/NEJMoa1805762 Immunotherapy combinations: http://doi.org/10.1056/NEJMp1803602 9 weeks that matter: http://doi.org/10.1016/S1470-2045(18)30752-6 Dr. Turner's seminal paper: https://doi.org/10.1056/NEJMsa065779

Natural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test donor natural killer cells in relapsed myeloma patients. The natural killer cells are collected and combined with IL-2 to help them grow and expand. Elotuzumab is used to help the NK cells migrate to the myeloma tumor and has anti-myeloma effect on its own. Learn more about this treatment that could help myeloma patients who are relapsed or refractory to standard myeloma therapies or help them bridge to other therapies like allogenic transplant or future CAR T studies.   Thanks to our episode sponsor, Celgene Corporation.

Dr Saad Usmani (Carolinas Healthcare System, Charlotte, USA) and Prof Thierry Facon (Hospitalière et Universitaire, Lille, France) discuss the latest data from ASH 2015 daratumumab and elotuzumab and the potential role of these monoclonal antibodies in the treatment of multiple myeloma. Daratumumab was recently approved for use in the USA becoming the first monoclonal antibody to be licensed for the treatment of relapsed/refractory multiple myeloma. Dr Usmani presented data from a combined analysis of two studies in heavily pretreated MM patients the meeting showing that single-agent daratumumab could produce an overall response rate of 31%. Elotuzumab has also recently received approval from the US Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior therapies. Long-term follow-up results of the ELOQUENT-2 study were presented at ASH 2015 showing that this monoclonal antibody can produce an effective and durable benefit.

Listen as Dr. Donald Harvey explains what he does if a patient has an infusion reaction on elotuzumab, even after premedication.

Dr Bezman talks to ecancertv at EHA 2016 about a novel immunotherapeutic combination tested in mouse models, combining PD-1 blockade therapy with elotuzumab, a SLAMF7 binding monoclonal antibody. SLAMF7 is overexpressed on the surface of tumour cells, and is also involved in the recruitment of NK T-cells. She reports that by combining these checkpoints inhibition with innate immune response, tumours are significantly reduced. Dr Bezman also comments on PD-1 targeting in solid and liquid tumours, and introduces ongoing clinical trials for advancing these mouse model results to human trials, which are currently recruiting patients.

Dr Meletios Dimopoulos (National and Kapodistrian University of Athens, Athens, Greece) talks to ecancertv at EHA 2015 about the results of ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone and is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Today in FirstWord: